Impact of Time from Diagnosis to Treatment on Outcomes of Adults with AML Treated with HMA and Venetoclax: A US-Based, Multi-Center, Real-World, Retrospective Analysis from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
Yates S, Weiss J, Sneider A, Geramita E, Guru Murthy G, Badar T, Im A, Lin C, Cheng W, Winer E, Abaza Y, Litzow M, Atallah E, Swaroop A, Patel A, Shallis R. Impact of Time from Diagnosis to Treatment on Outcomes of Adults with AML Treated with HMA and Venetoclax: A US-Based, Multi-Center, Real-World, Retrospective Analysis from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood 2024, 144: 447-447. DOI: 10.1182/blood-2024-207116.Peer-Reviewed Original ResearchDiagnosed AMLAcute myeloid leukemiaEuropean LeukemiaNetOverall survivalComplete responseECOG PSHypomethylating agentsSeverity of presentationMulti-centerPerformance statusRetrospective analysisFactors associated with improved OSTherapy-related acute myeloid leukemiaECOG PS of 2Initiation of induction therapyMultivariate analysisAssociated with worse OSNext generation sequencing panelIntermediate risk diseaseIncomplete count recoveryECOG performance statusDisease biologyNPM1 mutation statusUnivariate Cox modelPre-planned subgroup analysis